SCHEMBL2220140

SCHEMBL2220140

NC(=O)c1cnc(N)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 2/20 0.59
ADORA3 P0DMS8 1/20 0.50
TSHR P16473 1/20 0.50
MC4R P32245 1/20 0.50
ADRA1A P35348 1/20 0.50
MC3R P41968 1/20 0.50
NNMT P40261 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
GABRP O00591 4/20 0.43
GABRD O14764 4/20 0.43
GABRA1 P14867 4/20 0.43
GABRB1 P18505 4/20 0.43
GABRG2 P18507 4/20 0.43
GABRB3 P28472 4/20 0.43
GABRA5 P31644 4/20 0.43
GABRA3 P34903 4/20 0.43
GABRA2 P47869 4/20 0.43
GABRB2 P47870 4/20 0.43
GABRA4 P48169 4/20 0.43
GABRE P78334 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2635320 0.87 SIRT6 (0.73) SIRT6ADORA3TSHRMC4RADRA1A
SCHEMBL29475641 0.86 GABRP (0.48) SIRT6NNMTSMN1; SMN2GABRPGABRD
SCHEMBL2218717 0.86 GABRP (0.48) SIRT6NNMTSMN1; SMN2GABRPGABRD
Hydrochloric Acid SCHEMBL27917292 0.85 SIRT6 (0.70) SIRT6ADORA3TSHRMC4RADRA1A
SCHEMBL17712841 0.80 SIRT6 (0.64) SIRT6ADORA3TSHRMC4RADRA1A
SCHEMBL648809 0.79 SIRT6 (0.47) SIRT6NNMTSMN1; SMN2GABRPGABRD
SCHEMBL2655391 0.79 KCNJ1 (0.43) SIRT6NNMTSMN1; SMN2GABRPGABRD
SCHEMBL30803978 0.79 KCNJ1 (0.43) SIRT6NNMTSMN1; SMN2GABRPGABRD
SCHEMBL5041030 0.76 SIRT6 (0.59) SIRT6ADORA3TSHRMC4RADRA1A
SCHEMBL30489429 0.76 SIRT6 (0.59) SIRT6ADORA3TSHRMC4RADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092784-A1 CONDENSED HETEROCYCLIC COMPOUND NISSAN CHEMICAL CORPORATION (JP) 2024-03-21 US claimed
EP-4219500-A1 CONDENSED HETEROCYCLIC COMPOUND Nissan Chemical Corporation (JP) 2023-08-02 EP claimed
EP-2038264-B1 TETRAZOLE-SUBSTITUTED ARYLAMIDES HOFFMANN LA ROCHE (CH) 2016-10-26 EP claimed
US-20070079392-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2007-04-05 US claimed
US-20050004178-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2005-01-06 US claimed
US-20040142377-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2004-07-22 US claimed
EP-0625514-B1 2-Amino-pyrazin-5-carboxamid derivatives, their preparation and their use in therapy SYNTHELABO (FR) 1999-08-25 EP claimed
EP-0625514-A1 2-Amino-pyrazin-5-carboxamid derivatives, their preparation and their use in therapy SYNTHELABO (FR) 1994-11-23 EP claimed
US-20240092784-A1 CONDENSED HETEROCYCLIC COMPOUND NISSAN CHEMICAL CORPORATION (JP) 2024-03-21 US disclosed
CN-115260593-B Antibacterial agent for plastic based on nano silver and preparation method thereof 科迈特新材料有限公司 2023-11-21 CN disclosed
EP-4219500-A1 CONDENSED HETEROCYCLIC COMPOUND Nissan Chemical Corporation (JP) 2023-08-02 EP disclosed
CN-115260593-A Nano-silver-based antibacterial agent for plastics and preparation method thereof 科迈特新材料有限公司 2022-11-01 CN disclosed
WO-2021019514-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2021-02-04 WO disclosed
US-10201525-B2 Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists ROCHE PALO ALTO LLC (US) 2019-02-12 US disclosed
US-5420130-A Adrenergic blocking agents SYNTHELABO (FR) 1995-05-30 US disclosed
US-5420130-A Adrenergic blocking agents SYNTHELABO (FR) 1995-05-30 US disclosed
EP-0625514-A1 2-Amino-pyrazin-5-carboxamid derivatives, their preparation and their use in therapy SYNTHELABO (FR) 1994-11-23 EP disclosed
EP-0625514-A1 2-Amino-pyrazin-5-carboxamid derivatives, their preparation and their use in therapy SYNTHELABO (FR) 1994-11-23 EP disclosed
US-4659727-A ANTIARTHRITIC AGENTS MAY & BAKER LIMITED (GB) 1987-04-21 US disclosed
EP-0174832-A2 Ethene derivatives MAY & BAKER LIMITED (GB) 1986-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070079392-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders GPR119, ADIPOR2, GCGR SIRT6 731/4885ADORA3 130/4885TSHR 206/4885
US-10201525-B2 Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists P2RX2, P2RX3, TPX2 SIRT6 4115/4885ADORA3 116/4885TSHR 132/4885
US-20240092784-A1 CONDENSED HETEROCYCLIC COMPOUND SPR, QDPR, SUCNR1 SIRT6 1795/4885ADORA3 4102/4885TSHR 1622/4885
US-20050004178-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders GPR119, ADIPOR2, GCGR SIRT6 731/4885ADORA3 130/4885TSHR 206/4885
US-20040142377-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders GPR119, ADIPOR2, GCGR SIRT6 731/4885ADORA3 130/4885TSHR 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.